PMID- 26693077
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20151222
LR  - 20201001
IS  - 2156-6976 (Print)
IS  - 2156-6976 (Electronic)
IS  - 2156-6976 (Linking)
VI  - 5
IP  - 10
DP  - 2015
TI  - A multi-center phase II study of nintedanib as second-line therapy for patients 
      with advanced non-small-cell lung cancer in China.
PG  - 3270-5
AB  - PURPOSE: This study examined the efficacy and safety of using nintedanib as 
      single-regimen in 2(nd)-line chemotherapy for Chinese patients with advanced 
      (beyond stage IIIB) non-small-cell lung cancer (NSCLC). METHODS: Chinese patients 
      were those with stage IIIB or IV NSCLC and had unsuccessful 1(st)-line platinum 
      based chemotherapy. Patients received two oral intakes of 200 mg nintedanib 
      everyday from day 1 to day 21, on every 4-week cycle. Primary endpoint was 
      progression-free survival (PFS). Secondary endpoints included overall survival 
      (OS) and disease control rate. RESULTS: There were 62 eligible patients enrolled 
      in the study. Half of the patients were male (n = 31, 50.0%). The median age was 
      64.2 years with youngest age of 33 years and oldest age of 83 years. Median PFS 
      was 3.9 months (95% CI, 2.7-6.4 months). Median OS was 6.7 months (95% CI, 
      4.8-10.1 months). No patients (0.0%) had complete response. Thirty-one patients 
      (50.0%) had stable disease and 23 patients (37.1%) had partial response. The most 
      common severe adverse events (AEs), graded as 3 or 4, were heart failure (n = 12, 
      19.4%), hypertension (n = 7, 11.8%) and diarrhea (n = 6, 9.8%). CONCLUSION: NSCLC 
      Patients in 2(nd)-line chemotherapy reached similar PFS, as compared with other 
      FDA-approved second-line regimens. Also, the toxicity of nintedanib was well 
      tolerated. Thus, nintedanib may be used as a standard regimen for 2(nd)-line 
      chemotherapy for patients with advanced NSCLC.
FAU - Dai, Wenxin
AU  - Dai W
AD  - Fourth Ward of Medical Care Center, Hainan Provincial People's Hospital Haikou 
      570311, Hainan Province, China ; The First Xiangya Hospital of Central South 
      University, Central South University Changshai 410083, Hunan Province, China.
FAU - Luo, Bailing
AU  - Luo B
AD  - The First Xiangya Hospital of Central South University, Central South University 
      Changshai 410083, Hunan Province, China.
FAU - Wu, Zhiyong
AU  - Wu Z
AD  - Fourth Ward of Medical Care Center, Hainan Provincial People's Hospital Haikou 
      570311, Hainan Province, China.
FAU - Chen, Juan
AU  - Chen J
AD  - Fourth Ward of Medical Care Center, Hainan Provincial People's Hospital Haikou 
      570311, Hainan Province, China.
FAU - Feng, Guangqiu
AU  - Feng G
AD  - Fourth Ward of Medical Care Center, Hainan Provincial People's Hospital Haikou 
      570311, Hainan Province, China.
FAU - Guan, Ping
AU  - Guan P
AD  - Fourth Ward of Medical Care Center, Hainan Provincial People's Hospital Haikou 
      570311, Hainan Province, China.
LA  - eng
PT  - Journal Article
DEP - 20150915
PL  - United States
TA  - Am J Cancer Res
JT  - American journal of cancer research
JID - 101549944
CIN - Am J Cancer Res. 2016;6(7):1547-8. PMID: 27508096
PMC - PMC4656748
OTO - NOTNLM
OT  - Non-small-cell lung cancer
OT  - OS
OT  - PFS
OT  - nintedanib
OT  - second-line chemotherapy
EDAT- 2015/12/23 06:00
MHDA- 2015/12/23 06:01
PMCR- 2015/09/15
CRDT- 2015/12/23 06:00
PHST- 2015/05/19 00:00 [received]
PHST- 2015/06/13 00:00 [accepted]
PHST- 2015/12/23 06:00 [entrez]
PHST- 2015/12/23 06:00 [pubmed]
PHST- 2015/12/23 06:01 [medline]
PHST- 2015/09/15 00:00 [pmc-release]
PST - epublish
SO  - Am J Cancer Res. 2015 Sep 15;5(10):3270-5. eCollection 2015.